PD01.02. Renin–Angiotensin System Blockade During Neoadjuvant Therapy is Associated With Enhanced Tumor Regression and Survival in Esophageal Squamous Cell Carcinoma

Clicks: 21
ID: 325996
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #150 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Other Background Beyond blood pressure regulation, the renin–angiotensin system (RAS) has been implicated in tumor angiogenesis, stromal remodeling, and immune modulation. Pharmacologic blockade of this pathway through angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has demonstrated potential antineoplastic properties in several malignancies. Whether exposure to these agents during neoadjuvant treatment influences pathological response or long-term outcomes in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods We conducted a retrospective cohort study of 391 consecutive patients with ESCC who received neoadjuvant chemotherapy followed by curative-intent (R0) resection between 2015 and 2022. Patients were categorized according to the incidental use of angiotensin system inhibitors (ASIs) during neoadjuvant therapy. Clinicopathologic characteristics, major pathologic response (MPR), overall survival (OS), and disease-free survival (DFS) were compared between groups. Multivariable logistic and Cox regression models were applied to adjust for demographic and tumor-related covariates. Propensity score matching (PSM) was performed as a sensitivity analysis to mitigate baseline imbalances. Results Sixty-seven patients (17.1%) received ASIs during neoadjuvant treatment. Although ASI users were older and more frequently hypertensive, other oncologic characteristics were comparable. ASI exposure was independently associated with a higher likelihood of achieving MPR (adjusted OR 2.19, 95% CI 1.21–3.97; P = 0.010). During follow-up, ASI use correlated with significantly improved OS (adjusted HR 0.48, 95% CI 0.29–0.79; P = 0.004) and DFS (adjusted HR 0.56, 95% CI 0.36–0.90; P = 0.015). After propensity score matching, the survival advantage persisted for both OS (HR 0.38; P = 0.003) and DFS (HR 0.54; P = 0.038), supporting the robustness of the findings. Conclusion Incidental blockade of the renin–angiotensin system during neoadjuvant chemotherapy was associated with improved tumor regression and superior long-term survival in patients with ESCC. These data suggest a potential synergistic role of RAS inhibition in the perioperative setting and provide a rationale for prospective validation of this readily available pharmacologic strategy.
Reference Key
openalex_W7204011179 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maohui Chen, Yizhou Huang, Zhenyuan Yang, Taidui Zeng, Chun Chen, Bin Zheng
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.072
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.072/70760830/doag077.072.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.